Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesActivation and clinical significance of the unfolded protein response in breast cancer
British Journal of Cancer, 11/02/09
Scriven P et al. – The UPR is activated in the majority of breast cancers and confers resistance to chemotherapy. In vitro oestrogen stimulates UPR induction. UPR activation may contribute to breast cancer chemoresistance and interact with oestrogen response elements.
Methods- 395 human breast adenocarcinomas immunohistochemically stained for UPR activation markers (glucose-regulated protein (GRP-78 and XBP-1)
- Model of UPR activation in vitro by glucose deprivation of T47D breast cancer cells developed to determine how UPR affects cellular sensitivity to doxorubicin and 5-fluorouracil
- Cytotoxicity assessed using colorimetric cytotoxicity assay (MTT)
- Effect of oestrogen stimulation and tamoxifen exposure on UPR activation by T47D cells determined by western blotting measurement of key UPR protein, GRP-78
- Expression of GRP78 and XBP-1 demonstrated in 76% and 90% of breast cancers, respectively, and correlated with oestrogen receptor positivity
- In vitro UPR activation induced resistance to both doxorubicin and 5-flurouracil
- Oestrogen stimulation induced GRP78 and XBP1 over-expression on western blotting
- Tamoxifen did not block this response and may induce UPR activation
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Serum calcium levels are elevated among women with untreated postmenopausal breast cancer
Cancer Causes and Control, 11/03/09
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
Journal of Clinical Oncology, 10/29/09
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
Annals of Internal Medicine, 11/17/09
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
The association of metabolic syndrome with triple-negative breast cancer
Breast Cancer Research and Treatment, 10/28/09
Sponsor
Article Search
Sponsor
Sponsor